Graft-Versus-Host-Disease Clinical Trial
Official title:
Natural History and Pathophysiology of Gastrointestinal Graft Versus Host Disease
Verified date | February 4, 2013 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will determine the best location to biopsy the gastrointestinal (GI) tract for
early and accurate diagnosis of GI graft-versus-host-disease (GVHD). (A biopsy is the
surgical removal of a small piece of tissue for examination under the microscope.) GVHD is a
life-threatening complication of stem cell transplantation in which the donor s immune cells
destroy the patient s healthy tissues. It most commonly affects the skin, liver and GI tract.
This study will establish where to best biopsy tissue from the GI tract and study the tissue
to try to explore how GI GVD occurs and how it may be possible to better diagnose and treat
it.
Patients 18 years of age and older who have undergone or are who will undergo stem cell
transplantation and who are at high risk for developing GI GVHD may be eligible for this
study. Participants may enter the study before the transplant procedure or later if they
develop GVHD symptoms.
Participants undergo the following tests and procedures:
I. Before starting conditioning chemotherapy or radiation therapy for the transplantation
- Medical history and physical examination
- Sigmoidoscopy (endoscopy of the lower part of the large intestine) and biopsies
- Blood draw
- Stool sample collection
II. Two to 3 weeks after conditioning regimen
- Sigmoidoscopy with biopsies
- Blood draw
- Stool sample collection
III. 30, 45, 60 and 90 days after transplantation
-Blood draw
IV. After completing the tests in part II and at the appearance of GI symptoms suspected to
be due to GVHD
- Updated medical history and physical examination
- Esophagogastroduodenoscopy (endoscopy of the esophagus, stomach and upper small
intestine)
- Colonoscopy (endoscopy of the entire part of the large intestine) with biopsies
- Blood draw
- Stool collection
V. Two weeks after starting therapy in patients diagnosed with GVHD
- Sigmoidoscopy with biopsies
- Blood draw
- Stool sample collection
- PET/CT scan in selected patients (nuclear medicine and x-ray imaging of the GI tract
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 4, 2013 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: All patients 18 years or older who have undergone or plan to undergo any type of allogeneic bone marrow or peripheral stem cell transplant. (This will be coordinated with all different institutes at NIH to involve patients who participate in NIH affiliated protocols.) EXCLUSION CRITERIA: 1. Patients who are under the age of 18 years. 2. Patients with a platelet count less than 30,000/mm(3). 3. Patients with an elevated prothrombin or partial thromboplastin time more than 1.5 times greater than the upper limit of normal or an absolute neutrophil count less than 500/mm(3) of blood or a history of a bleeding diathesis. 4. Women who are pregnant, as determined by laboratory evaluation performed according to the referring transplant protocol, or breast feeding. 5. Patients who are unable to provide informed consent. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett AJ, Horowitz MM, Socié G; Société Française de Greffe de Moëlle et Thérapie Cellulaire; Dana Farber Cancer Institute; International Bone Marrow Transplant Registry. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005 Aug 15;106(4):1495-500. Epub 2005 May 5. — View Citation
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56. — View Citation
Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ, Nash RA, Petersdorf EW, Hansen JA, Storb R. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2004 May;10(5):320-7. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04792580 -
The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease
|
Early Phase 1 | |
Not yet recruiting |
NCT05969743 -
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease
|
Phase 2 | |
Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
Completed |
NCT04014790 -
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT06008808 -
Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT03395860 -
Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT
|
Phase 2 | |
Completed |
NCT03207958 -
Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
|
Phase 1 | |
Completed |
NCT03414645 -
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
|
Phase 1/Phase 2 | |
Completed |
NCT03846479 -
Itacitinib for Low Risk GVHD
|
Phase 2 | |
Active, not recruiting |
NCT01927120 -
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
|
Phase 2 | |
Recruiting |
NCT06321003 -
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
|
||
Not yet recruiting |
NCT06279585 -
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
|
N/A | |
Not yet recruiting |
NCT06392711 -
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
|
Phase 1 | |
Suspended |
NCT05617625 -
CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome
|
Phase 2 | |
Recruiting |
NCT03148197 -
Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)
|
N/A | |
Recruiting |
NCT03456817 -
HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis
|
Phase 2 | |
Completed |
NCT00827398 -
Treatment of Steroid Resistant GVHD by Infusion MSC
|
Phase 1/Phase 2 | |
Recruiting |
NCT03842696 -
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT03605927 -
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
|
Phase 1 | |
Recruiting |
NCT04688021 -
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
|
Phase 2 |